Human Antihistamine Drug Market Size & Share, by Drug Type (Second-Generation Antihistamines, First-Generation Antihistamines); Type, Indication, Route of Administration; End Users - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Human Antihistamine Drug Industry - Regional Synopsis

North America Market Analysis

North America human antihistamine drug market is projected to capture revenue share of around 42.5% by the end of 2037. The growth is attributed to the region’s competitive environment, strategic alignment between key companies, as well as continuous progress and development of novel therapies. In addition, the region has a strong market presence for the manufacturing, production, and commercialization of antihistamines to make them easily available for the population affected by disorders. Also, the prevalence of regulatory bodies and governments is yet another factor that is suitable for the market to gain more popularity.

The human antihistamine drug market in the U.S. is significantly growing due to the newest innovations in the healthcare sector by administrative organizations. For instance, in January 2025, the U.S. FDA accepted the two medications, namely Nemluvio, which is an IL-31 inhibitor biologic developed by Galderma for people over 12 years of age with reasonable and unadorned atopic dermatitis. Additionally, the organization also approved Vtama, which is an aryl hydrocarbon receptor agonist and nonsteroidal topical cream for the ailment of children and adults suffering from the same condition, thus boosting the market.

The human antihistamine drug market in Canada is gaining more traction owing to the launch of the latest treatment solutions by regional organizations. For instance, in February 2025, Pharmascience Canada declared the unveiling of pms-RUPATADINE (rupatadine). It is a treatment that benefits and relieves nasal and non-nasal symptoms of periodic allergic rhinitis, perennial allergic rhinitis, as well as symptoms related to chronic spontaneous urticaria. Therefore, with such introductions of health solutions, the country is effectively focused on expanding the market to cater to the population and their well-being.

APAC Market Statistics

The Asia Pacific human antihistamine drug market is expected to be the fastest-growing region during the forecast period. Factors such as the presence of regulatory guidelines approved by experts and the increased implementation of antihistamines are readily responsible for the upliftment of the market. Besides, there is a huge burden of chronic urticaria in the region, which is present in both spontaneous and inducible forms, driving the demand for antihistamine therapy for patients affected with severe nausea conditions.

There is a huge necessity for the human antihistamine drug market in India since there is a high prevalence of asthma. As stated in a cross-sectional study published by the India Journal of Immunology and Respiratory Medicine in October 2024, 15% of the population in the country suffering from allergy develop asthma. In addition, an estimated 80% of adults and 75% of children are affected by asthma, which is eventually increasing. Therefore, to keep a check on the occurrence, there is a huge demand for antihistamine drug therapy in the country, which denotes a positive impact on the market upliftment.

The human antihistamine drug market in China is rapidly growing owing to factors such as economic development, an increase in medical expenditure, and the growing incidence of health conditions. Besides, the country is subject to the presence and availability of herbal medicines to aid any health conditions. According to an analytical study published by NLM in June 2022, the incidence of itchy nose was 0.18 to 0.82, runny nose was 0.05 to 0.39, and sneezing was 0.29 to 1.15 in the country. Therefore, all these conditions resulted in the increased demand for antihistamine drugs to get rid of these conditions, thereby ensuring market upliftment.